Početna stranicaALNOV • EPA
add
Novacyt SA
Preth. zaklj. cijena
0,58 €
Dnevni raspon
0,57 € - 0,59 €
Godišnji raspon
0,49 € - 1,59 €
Tržišna kapitalizacija
40,30 mil. EUR
Prosječna količina
299,24 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
EPA
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(GBP) | lip 2024.info | Godišnja promjena |
---|---|---|
Prihod | 5,16 mil. | 209,13 % |
Operativni troškovi | 7,92 mil. | 92,89 % |
Neto dohodak | −8,85 mil. | −112,01 % |
Neto profitabilnost | −171,47 | 31,41 % |
Zarada po dionici | — | — |
EBITDA | −12,02 mil. | −324,07 % |
Efektivna porezna stopa | 1,22 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(GBP) | lip 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 32,95 mil. | −59,69 % |
Ukupna imovina | 99,40 mil. | −24,78 % |
Ukupne obveze | 28,99 mil. | 16,70 % |
Ukupni kapital | 70,41 mil. | — |
Dionice u optjecaju | 70,63 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,58 | — |
Povrat imovine | −36,30 % | — |
Povrat kapitala | −43,18 % | — |
Tok novca
Neto promjena novca
(GBP) | lip 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | −8,85 mil. | −112,01 % |
Gotovina od poslovanja | −4,54 mil. | −59,67 % |
Gotovina iz ulaganja | −566,50 tis. | −212,18 % |
Gotovina iz financiranja | −430,50 tis. | −61,24 % |
Neto promjena novca | −5,56 mil. | −112,16 % |
Slobodan tok novca | −17,73 mil. | −943,16 % |
Više
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Glavni izvršni direktor
Osnovano
2006
Web-lokacija
Zaposlenici
240